Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions

A Phase I Clinical Study to Evaluate the Tolerance and Safety of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesion(s) (CIN 2 and 3)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00989443

Enrollment

Registered

2009-10-05

Start date

2010-05-31

Completion date

Unknown

Last updated

2010-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervix Intraepithelial Neoplasia, Uterine Cervical Neoplasms

Keywords

Cervix Intraepithelial Neoplasia grades 2 and 3

Brief summary

Human Papilloma Virus (HPV) infections induce cervical intraepithelial neoplasia (CIN) of cervix. To reduce incidence of invasive tumor associated with high grade CIN lesions, the standard treatment is the conisation of cervix (surgical act). A local treatment with the antiviral and anti-proliferative cidofovir would preserve the cervix of young subjects and reduce obstetrical morbidity induced by the conisation. This clinical study is aimed at : 1. evaluating the tolerance and safety of a cidofovir gel directly applied on the cervix exhibiting high grade CIN lesions; 2. evaluating the pharmacokinetic (PK) profile of cidofovir after local application.

Interventions

DRUGCidofovir gel

topical gel applied once a week for 3 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* women aged between 18 and 50 years old * volunteers * informed consent signed * cervical lesion classified CIN 2 or 3, on a biopsy made during the 6 preceding weeks * no sexual activity or use of effective mechanical, hormonal or intrauterine contraception (except hormonal vaginal ring)

Exclusion criteria

* pregnancy or breast feeding * subtotal hysterectomy * current or ancient renal impairment * current immune disorder * current use of drugs interfering with renal function * current treatment for any cancer * current use of treatment interfering with immunity * current use of anti-viral treatment * current or recent participation to another experimental study during the last 3 months before the screening visit * current vaginal application of drugs or cosmetics * local or general condition incompatible with the experimental treatment in the opinion of the principal investigator

Design outcomes

Primary

Measure	Time frame
adverse events	weeks 1, 2, 3 and 4

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026